MedTrace Logo

Outcome of Different IOLs in Patients With and Without Uveitis

NCT02975895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-08-30

No results posted yet for this study

Summary

Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual acuity. In most cases it can be managed with surgery, removing the own lens and replacing it with an artificial lens, intraocular lens (IOL). These lenses are made in different materials with different properties.

Uveitis refers to an inflammation in the iris, ciliary body and choroid. Patients with this disease have an increased risk of developing cataract due to the inflammation itself and treatment with steroids. They also have an increased risk of complications during surgery and postoperatively. In this group the selection of IOL might be of greater importance.

The aim of this prospective randomized controlled study is to compare the outcome of hydrophobic and hydrophilic intraocular lenses in patients with and without uveitis

Conditions

  • Uveitis
  • Cataract
  • Inflammation
  • Posterior Capsule Opacification

Interventions

DEVICE

Hydrophobic IOL: Vivinex (HOYA)

Patients requiring cataract surgery will be randomized to one of the two types of IOLs.

DEVICE

Hydrophilic IOL: INCISE (Bausch+Lomb)

Patients requiring cataract surgery will be randomized to one of the two types of IOLs.

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Madeleine Zetterberg, MD, PhD · Västra Götalands regionen, Sahlgrenska University Hospital, Department of Ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2021-02-22
Completion
2022-03-17

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975895 on ClinicalTrials.gov